Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.2.3.0-1 | Award Amount: 6.97M | Year: 2013
Effectively protecting the general population from seasonal and pandemic influenza has proven to be a challenge, since influenza viruses continue to escape from and evade immunity. Current influenza vaccines fail to provide long-lasting and broad protection against multiple strains of influenza. For the development of a universal influenza vaccine, we have to do better than Nature, since even natural influenza virus infections fail to induce broad protective immunity. To induce broad-protective and long-lasting immunity an influenza vaccine should therefore be directed to conserved viral proteins or regions thereof that are insufficiently exposed upon natural infection. FLUNIVAC is a SME-targeted collaborative research project that aims to develop a candidate influenza vaccine based on recombinant MVA expressing both antibody and T-cell response-inducing proteins, ready to commence Phase I clinical trials within 4 years. We will generate recombinant MVAs that express nine conserved (regions of) influenza A virus proteins (surface proteins HA, NA, M2e, internal proteins M1, NP, NS1, and the polymerase proteins PB1, PB2, PA). These proteins are targets for both antibody and T-cell mediated immune responses, since the induction of solely one of both affords only modest protection against infection with influenza viruses of heterologous subtypes. These recombinant MVAs will be tested for their capacity to induce the desired broad-protective immune response individually and in selected combinations in vivo. In parallel, MVA-induced immune responses will be tested for their longevity and boostability as compared with those induced with adjuvanated vaccine preparations. Furthermore, the MVA platform will be optimized in terms of: i) kinetics and extent of protein-expression of the MVA vector to optimally activate the respective arms of the immune system; ii) a viable unified production process, independent of embryonated chicken eggs, will be designed and implemented.
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.1.3-3 | Award Amount: 8.14M | Year: 2013
Cardiovascular disease (CVD) is still a leading cause of death in the European Union (EU) accounting for nearly half of all deaths in Europe (48%). In addition, CVD complications lead to a vast number of hospitalizations and thus to a great burden of health care costs in the EU. Atherosclerosis and its final complication, plaque rupture and subsequent infarct in heart or brain, is the main underlying pathology of CVD and atherosclerosis is responsible for 70% of all cases of CVD. Extensive studies into the pathology of atherosclerosis show that its etiology is found in a combination of dyslipidemia and a related inflammatory response with an established autoimmune component, while the major cause of acute CVD events, plaque rupture, due to an inflammatory destabilization of the atherosclerotic lesion. CVD is therefore an autoimmune-like disease in the context of a metabolic disease. Thus far, therapeutic approaches in CVD have been focused at normalizing dyslipidemia in order to lower plasma cholesterol. Statins and additional surgical approaches such as angioplasty have achieved a 30% risk reduction for CVD during the last 10-15 years. However, additional approaches to improve the treatment of dyslipidemia by for instance improving the level of the anti-atherogenic lipoprotein HDL have failed in a number of clinical trials. This implicates that new therapeutic approaches are urgently needed to narrow down the remaining 70% risk for CVD. We aim to develop a new immunomodulatory treatment, a therapeutic vaccine that permanently restores the immune balance within the arterial wall by inhibiting the inflammatory responses during atherosclerosis. The VIA consortium aims to develop a vaccine, dissect the immune pathways underlying the beneficial effect of the vaccine, optimize the vaccine, test its safety and perform a phase I clinical trial using the atheroprotective vaccine. The vaccine is foreseen to result in a substantial lowering of the risk for CVD.
Agency: European Commission | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-2011-ITN | Award Amount: 4.30M | Year: 2012
STROMA is an Initial Training Network promoting the study of stromal cell immune system interactions during stroma development and function in health and disease. In STROMA we have bought together world leading experts from academia and industry in Europe to address the key scientific questions in this emerging field. STROMA will promote the training of three Experienced Researchers (ER) and seventeen Early Stage Researchers (ESR) combining research and training in state-of-the-art multidisciplinary technologies. Through hands on and a Virtual Learning Environment STROMA will train the ESRs in the latest imaging, animal models, genomics, infectious biology and stromal biology technologies in collaboration with our industrial partners. STROMA will provide training in communications skills, ethics, plagiarism, grant writing, intellectual property rights, industrial skills training, project management, entrepreneurship, research policy, commercial exploitation of results and public engagement and develop a Personal Training Plan for each ESR and ER. Through network meetings and localized training the ESRs will receive additional training in complementary skills. STROMA is a highly interconnected network with each ER/ESR project involving multiple collaborations and secondments with other network participants including an extensive placement with our industrial partners. The importance of stromal cells and the molecular mechanism of stromal cell function in the regulation of immune responses have only recently been appreciated and are an exciting new area in immunology. The purpose of STROMA is to ensure that Europe retains global leadership in this emerging field and translates basic research on stroma-immune cell interactions to novel products and technologies for European industry.
Giese C.,ProBioGen AG |
Marx U.,TU Berlin
Advanced Drug Delivery Reviews | Year: 2014
It has been widely recognised that the phylogenetic distance between laboratory animals and humans limits the former's predictive value for immunogenicity testing of biopharmaceuticals and nanostructure-based drug delivery and adjuvant systems. 2D in vitro assays have been established in conventional culture plates with little success so far. Here, we detail the status of various 3D approaches to emulate innate immunity in non-lymphoid organs and adaptive immune response in human professional lymphoid immune organs in vitro. We stress the tight relationship between the necessarily changing architecture of professional lymphoid organs at rest and when activated by pathogens, and match it with the immunity identified in vitro. Recommendations for further improvements of lymphoid tissue architecture relevant to the development of a sustainable adaptive immune response in vitro are summarized. In the end, we sketch a forecast of translational innovations in the field to model systemic innate and adaptive immunity in vitro. © 2014 Elsevier B.V.
ProBioGen AG | Date: 2010-06-23
This application relates to cells that permanentely sustain a heat shock cascade without undergoing apoptosis.
Probiogen Ag | Date: 2012-05-14
The present invention relates to a cell for producing a secreted protein comprising a polynucleotide comprising a nucleic acid sequence encoding a fast cycling cdc42 mutant and a polynucleotide comprising a nucleic acid sequence encoding a secreted protein. It also relates to a method for producing said cell and to a method for producing a secreted protein using said cell.
Probiogen Ag | Date: 2011-11-23
It is desirable to produce live vaccines, which are highly attenuated and which do only contain minimal or no animal-derived components. The production of highly attenuated live viruses can be better achieved when using specifically designed cell lines as producer substrate as opposed to using less defined primary cells. However, live viruses, thus produced comprise undesirable components from the cell lines and cell culture. The present invention relates to methods of production and purification of live enveloped viruses, which are suitable for vaccination.
Probiogen Ag | Date: 2012-07-26
The present invention relates to immortalized avian cell lines suitable for production of biologicals or viruses for vaccination. In particular, the cell lines are derived from primary cells which are transformed with at least two viral or cellular genes, one of which causes cell cycle progression whereas the other interferes with innate protective mechanisms of the cell induced by dysregulated replication. The invention moreover relates to the production of said immortalized cell lines and their use for producing biologicals or viruses for vaccination.
ProBioGen AG | Date: 2012-05-31
The present invention relates to eukaryotic cells for producing molecules having an atypical fucose analogue on their glycomoieties and/or amino acids. It also relates to methods for producing molecules having an atypical fucose analogue on their glycomoieties and/or amino acids and to molecules obtainable by said methods. It further relates to methods for producing conjugates comprising molecules having an atypical fucose analogue on their glycomoieties and/or amino acids and pharmaceutical active compounds and to conjugates obtainable by said methods. In addition, the present invention relates to specific conjugates.
Probiogen AG | Date: 2012-09-28
The present invention relates to a novel Modified Vaccinia Ankara (MVA) virus. The present invention also relates to a method for culturing said MVA virus and to a method for producing said MVA virus. Further, the present invention relates to a pharmaceutical composition comprising said MVA virus and one or more pharmaceutical acceptable excipient(s), diluent(s), and/or carrier(s). Furthermore, the present invention relates to a vaccine comprising said MVA virus. In addition, the present invention relates to said MVA virus for use in medicine.